Article

Low-risk prostate cancer well managed with active surveillance

Author(s):

Leonard S. Marks, MD,Scott B. Shappell, MD, PhD

Drs. Scott B. Shappell and Leonard S. Marks discuss clinical use of urine PCA3 mRNA testing for prostate cancer.

Related Videos
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Final Thoughts and Clinical Trials in NMIBC
Final Thoughts and Clinical Trials in NMIBC
Uptake of New Treatments in Urology Practice
Uptake of New Treatments in Urology Practice
Patient Communication and Treatment Adherence in NMIBC
Patient Communication and Treatment Adherence in NMIBC
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Ian Metzler, MD, highlights recent advances in kidney stone technology
Ian Metzler, MD, highlights recent advances in kidney stone technology
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Sima Porten, MD, on gene-environment interactions in bladder cancer development
1 expert in this video
Resective Surgery and Minimally Invasive Procedures For BPH
Naeem Bhojani, MD, expands on key findings from WATER III trial
Naeem Bhojani, MD, expands on key findings from WATER III trial
Related Content
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
April 17th 2025

NMIBC Clinical Forums highlight novel therapies and treatment strategies

Urology Times staff
Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Gene variant associated with increased risk of BPH
April 16th 2025

Gene variant associated with increased risk of BPH

Hannah Clarke
Data showed a significant association between the C allele of the SNP-765G>C of the PTGS2 gene and BPH.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
3d rendered medically accurate illustration of prostate cancer | Image Credit: @ Sebastian Kaulitzki - stock.adobe.com
April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke
The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.
FDA approval sought for Anktiva in papillary NMIBC
April 15th 2025

FDA approval sought for Anktiva in papillary NMIBC

Hannah Clarke
The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.
© 2025 MJH Life Sciences

All rights reserved.